Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing
Condition(s) studied
Investigational drug(s) / intervention(s)
No intervention: No intervention
Study summary
Prostate cancer is one of the most common malignancies in the male genitourinary system, and it is also the cancer with the fastest-growing incidence and mortality rates among men in China. Although prostate cancer screening can significantly reduce mortality, China has not yet established a well-developed screening system, which is one of the reasons why its mortality rate remains notably higher than that of Western countries. The primary objective of this project is to establish an efficient screening-diagnosis-treatment pathway, beginning with screening in community hospitals, followed by definitive diagnosis in secondary hospitals, and finally treatment in tertiary hospitals. Additionally, the project aims to achieve multi-institutional and multi-terminal sharing of disease information as well as dynamic monitoring and follow-up. The feasibility and effectiveness of this model will be validated through statistical analysis of the data.
Eligibility
Primary outcome measure(s)
- Serum PSA level — from 2025 to 2027
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Department of Urology, Peking University First Hospital, Beijing, 100034 | Beijing | China | Recruiting |
More Peking University First Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07319923 on ClinicalTrials.gov ↗ ← All trials in China